TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular diagnostics, announced today that is has formed a Scientific Advisory Board (SAB) that will provide technical and strategic input to its Board of Directors and Management team. The SAB includes a group of medical professionals with the necessary subject matter expertise to support the diverse business interests of TrovaGene in the areas of cancer, infectious disease, organ transplantation and prenatal transrenal molecular diagnostics.

The following individuals have joined its SAB: Dr. Riccardo Dalla-Favera (Director, Institute for Cancer Genetics and Herbert Irving Comprehensive Cancer Center, Columbia University, New York), Dr. Brunangelo Falini (Director – Institute Hematology, University of Perugia, Italy), and Dr. Sinuhe Hahn (Head of Research – Prenatal Medicine, University of Basel, Switzerland). TrovaGene plans to expand its SAB by 4 to 5 members over the next several months.

“We are pleased that these influential thought leaders have agreed to join our Scientific Advisory Board,” commented Dr. Tom Adams, TrovaGene’s Chairman of the Board, “Their scientific and medical input will be very valuable as we continue to build our global molecular diagnostics business.”

About TrovaGene,Inc.

With its headquarters and product development in San Diego, California, TrovaGene has focused on development of tests using its patented transrenal nucleic acid technology. Transrenal DNA (Tr-DNA) and RNA (Tr-RNA) are short nucleic acid fragments from infectious organisms or normal cell death that cross the kidney barrier and can be detected in urine. Safe and simple urine collection and analysis can replace biopsy or blood sampling and has a broad range of applications, including tumor detection and monitoring, infectious disease detection, prenatal testing, tissue transplantation, genetic testing for forensic identity determination, and testing associated with drug development. The TrovaGene molecular diagnostics assays will provide information that will enable physicians to provide personalized medical care for their patients.

TrovaGene has a dominant patent position as it relates to transrenal molecular testing. Issued U.S. and European patents cover any and all testing for molecular targets that pass through the kidney. In addition to these core patents, TrovaGene has numerous patent applications pending in the areas of cancer, infectious diseases, transplantation, prenatal and genetic testing. This patent position rivals the importance of the Roche PCR and Gen-Probe ribosomal RNA patents in the molecular diagnostic field.

Statements about TrovaGene's expectations, applications of its technology, markets, and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product development, government regulation, market acceptance, and dependence on key personnel, obtaining financing and other factors.